ChemMedChem · 2014 · 29 citations · 17 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsAntiparasitic AgentsAntiparasitic PharmacologyEnzyme InhibitionHit-to-lead OptimizationMalariaStructure-activity Relationship AnalysisAntimalarial AgentsAntimalarial ChemotherapyAntimalarial Drug DevelopmentAntiparasitic Drug DesignAntiparasitic Drug DiscoveryCap AnaloguesNovel Antiparasitic Compound ClassesPlasmodium Falciparum
Histone deacetylase (HDAC) inhibitors are an emerging class of potential antimalarial drugs. We investigated the antiplasmodial properties of 16 alkoxyurea-based HDAC inhibitors containing various cap and zinc binding groups (ZBGs). Ten compounds displayed sub-micromolar activity against the 3D7 line of Plasmodium falciparum. Structure-activity relationship studies revealed that a hydroxamic acid ZBG is crucial for antiplasmodial activity, and that the introduction of bulky alkyl substituents to cap groups increases potency against asexual blood-stage parasites. We also demonstrate that selected compounds cause hyperacetylation of P. falciparum histone H4, indicating inhibition of one or more PfHDACs. To assess the selectivity of alkoxyurea-based HDAC inhibitors for parasite over normal mammalian cells, the cytotoxicity of representative compounds was evaluated against neonatal foreskin fibroblast (NFF) cells. The most active compound, 6-((3-(4-(tert-butyl)phenyl)ureido)oxy)-N-hydroxyhexanamide (1 e, Pf3D7 IC50 : 0.16 μM) was 31-fold more toxic against the asexual blood stages than towards normal mammalian cells. Moreover, a subset of four structurally diverse HDAC inhibitors revealed moderate activity against late-stage (IV-V) gametocytes.
17
Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria
Arjen M. Dondorp, François Nosten, Poravuth Yi et al. · New England Journal of Medicine · 2009 · 3.5K citations · Full text